Supreme Court’s looming mifepristone decision leaves abortion rights in spotlight

The Supreme Court is expected to rule this summer on whether to restrict access to medication abortion, with the issue promising to be at the center of the 2024 election.

The justices will hear a case considering federal approval of the popular abortion drug mifepristone, with a ruling likely in June. Five months before voters decide between the White House and Congress, and almost exactly two years after the high court overturned the constitutional right. To abortion.

Both parties are currently preparing for one of the first abortion cases brought by the Supreme Court since the Roe v. Wade reversal. This legal sea change excited voters for Democrats and annoyed Republicans at polling places and election venues.

Democrats, who are focusing on abortion rights in 2024, believe the mifepristone case will further sway voters in battleground states.

“if [the decision] as a result in some way [mifepristone] If it's not available, it's just another earthquake,'' said Anna Greenberg, a Democratic pollster who has worked for Planned Parenthood and reproductive freedom for all.

More top articles from The Hill

Even though the high court agreed to hear the case in December, it added several major abortion cases and rulings that have rocked the country and emboldened Democrats. That same week in December, the Texas Supreme Court ruled against a woman who sought an emergency abortion and fled the state to receive the procedure. And last week, a federal appeals court ruled that health care providers in Texas are not required to provide access to abortions in emergency care.

“The more women have to refight these battles, the more Democrats will have to fight alongside them. And the more these conversations continue, the more voters will become particularly active on the issue.” They're going to go to the polls and vote,'' said Jennifer Holdsworth, a Democratic strategist who was prescribed mifepristone for a past miscarriage.

Holdsworth says she feels this issue personally.

“I don’t want Republicans or the U.S. Supreme Court to dictate what conversations I can have with my doctor,” she said. “Republicans don't seem to understand that.”

Strategists say the issue could also help energize people of color and younger voters, key voting blocs that President Biden and Democrats hope to regain momentum in 2024. It has said.

“I think it's beneficial in that sense to inspire the younger generation to make sure those rights are upheld. And I'm thinking especially of Black women, because we're disproportionately affected by this issue. Because we know that we're being impacted in a big way,” said April Turner, vice president of communications and external affairs at Higher Heights for America PAC, an organization that aims to increase the number of progressive black women. he said. To the office.

But Republicans and abortion rights opponents say the high court's decision to hear the case, and ultimately the abortion rights debate, has weighed on Republicans this election season. Democrats argue that whether or not to restrict Fepristone is of no use.

“I think Democrats mistakenly think this is going to be in their political interest in 2024,” said Greg Keller, a Republican strategist and former executive director of the Faith and Freedom Coalition. He expressed skepticism that the Supreme Court's decision to take up the case would ultimately galvanize the Democratic base and key voting blocs.

“If Missourians and Americans knew exactly what they wanted in this matter, they would realize that it is just part of a larger kind of culturally radical view of the modern Democratic Party. I think you'll notice,” he said. He said.

Similarly, Kristan Hawkins, president of the anti-abortion group Students for Life of America, said Democrats were “likely overstating” their support for abortion.

Greenberg pointed to election results from the past two years and rejected the idea that Democrats are overestimating the role abortion will play in 2024.

“It's already true that abortion boosted Democratic turnout in 2023 in Virginia and New Jersey and Ohio,” she said. “The idea that it's exaggerated or that it was a '2022' problem is because of the data, in terms of what people are communicating in elections and how that's impacting the outcome. It’s not substantiated.”

In December, the Supreme Court ruled against the Biden administration and the makers of mifepristone, seeking to overturn a lower court ruling that blocked access to the drug and imposed other restrictions, even in states where abortion remains legal. Agreed to hear the appeal. More than half of abortions in the United States are medication abortions, and mifepristone is associated with lower mortality rates than Viagra or colonoscopies, according to the Guttmacher Institute. According to court filings.

At the heart of this case is the Food and Drug Administration's (FDA) approval process for mifepristone, specifically the guidance that has been in place since 2016. The FDA loosened some restrictions on the drug during the approval process, including expanding the period during which patients can take the pill from seven weeks to 10 weeks of pregnancy.

F.D.A. online notes Mifepristone still requires a prescription, and the American College of Obstetricians and Gynecologists and several other societies said in court briefs that adverse events account for 0.3 percent of cases.

But the Alliance Defending Freedom, which represents anti-abortion plaintiffs, argues that: Filing a cross petition The FDA's approval process for mifepristone has “consistently prioritized politics over law, science, and safety,” he said, calling the FDA's recent actions to loosen some restrictions “an important issue surrounding its use.” “This is a recent decision to remove safeguards.”

Access to mifepristone is likely still available, given that the scope is primarily due to FDA changes starting in 2016, but the Supreme Court rules in favor of anti-abortion plaintiffs. If so, more restrictions are likely to be imposed.

Republicans and abortion rights opponents have objected to the FDA's loosening of regulations on mifepristone, including eliminating the need for an in-person doctor's visit to obtain the abortion pill and allowing prescriptions to be mailed.

Katie Daniel, director of national policy for the anti-abortion group Susan B. Anthony Pro-Life America, said in a statement to The Hill that the incident “exposes the Democratic Party's dangerous mail-order abortion drug scheme nationally. “It will be,” he claimed.

Abortion rights advocates say voters won't be swayed at the polls this November.

“Voters know how they feel about their rights being taken away after the Dobbs decision, and have made it clear repeatedly. They don't support it,” Planned Parenthood Action Fund said. Jacqueline Ayers, senior vice president of policy, campaigns and advocacy, said in a statement.

“Everyone should have the right to make decisions about their body, life and future. That includes access to safe and effective mifepristone nationwide, and this case threatens to undermine that.” ” she added.